Advertisement

Clinical Classification and Incidence of Malignant Hyperthermia in Australia

  • Michael A. Denborough
Conference paper

Abstract

We classify malignant hyperthermia (MH) into the three myopathies that predispose to the anesthetic complication. These are as follow.

Keywords

Neuroleptic Malignant Syndrome Malignant Hyperthermia Malignant Hyperthermia Serum Creatine Kinase Neuroleptic Drug 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Denborough MA, Lovell RRH (1960) Anaesthetic deaths in a family. Lancet 2: 45CrossRefGoogle Scholar
  2. 2.
    Denborough MA, Ebeling P, King JO, Zapf P (1970) Myopathy and malignant hyperpyrexia. Lancet 1: 1138–1140PubMedCrossRefGoogle Scholar
  3. 3.
    Harriman DGF, Sumner DW, Ellis FR (1973) Malignant hyperthermia myopathy. Q J Med 42: 639–664PubMedGoogle Scholar
  4. 4.
    Denborough MA, Dennett X, Anderson RMCD (1973) Central-core disease and malig-,. nant hyperpyrexia. Br Med J 1: 272–273PubMedCrossRefGoogle Scholar
  5. 5.
    King JO, Denborough MA (1973) Anesthetic-induced malignant hyperpyrexia in children. J Pediatr 83: 37–40PubMedCrossRefGoogle Scholar
  6. 6.
    Rosenberg H (1982) The clinical syndrome of malignant hyperpyrexia. In: Proceedings of the Third International Workshop on Malignant Hyperpyrexia. Banff, Alberta, Canada, p 3Google Scholar
  7. 7.
    Denborough MA (1982) Heat stroke and malignant hyperpyrexia. Med J Aust 1: 204–205Google Scholar
  8. 8.
    Denborough MA, Collins SP, Hopkinson KC (1984) Rhabdomyolysis and malignant hyperpyrexia. Br Med J 288: 1878CrossRefGoogle Scholar
  9. 9.
    Denborough MA, McLean A, Morgan G, Hopkinson KC (1994) Fatal inherited rhabdomyolysis and malignant hyperthermia. Lancet 343: 236–237PubMedCrossRefGoogle Scholar
  10. 10.
    Collins SP, White MD, Denborough MA (1988) Calmodulin antagonist drugs and malignant hyperpyrexia. Clin Exp Pharmacol Physiol 15: 473–477PubMedCrossRefGoogle Scholar
  11. 11.
    Denborough MA, Galloway GJ, Hopkinson KC (1982) Malignant hyperpyrexia and sudden infant death. Lancet 2: 1068–1069PubMedCrossRefGoogle Scholar
  12. 12.
    Peterson DR, Davis N (1986) Sudden infant death syndrome and malignant hyperthermia diathesis. Aust Paediatr J 22 (Suppl): 33–35PubMedGoogle Scholar
  13. 13.
    Denborough MA, Hopkinson KC (1994) Death caused by overheating in piglets susceptible to malignant hyperthermia. Med J Aust 160: 731–732PubMedGoogle Scholar
  14. 14.
    Denborough MA, Hopkinson KC (1988) Firefighting and malignant hyperthermia. Br Med J 296: 1442–1443CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Tokyo 1996

Authors and Affiliations

  • Michael A. Denborough
    • 1
  1. 1.Division of Biochemistry and Molecular BiologyThe John Curtin School of Medical Research, Australian National UniversityCanberraAustralia

Personalised recommendations